How to Buy AR1001 by Arivivo: Current Status and Price Comparison


How to Buy AR1001 by Arivivo: Current Status and Future Outlook
Arivivo's Alzheimer's treatment drug AR1001 has not yet been released on the market. The company aims to submit for approval in the second half of 2026, following the completion of global Phase 3 clinical trials and data analysis. Purchasing is currently impossible, and an exact price cannot be predicted before official announcement.
Development Status and Approval Timeline
Arivivo's AR1001 has gained attention as the world's first oral dementia treatment drug. It was presented at the World Congress of Neurology in September 2025, and previously completed Phase 2 clinical trials with the U.S. FDA. As of March 2026, the progress of Phase 3 clinical trials exceeded 90%, and on July 27, 2026, global Phase 3 trials officially concluded, with a focus now on data analysis.
Arivivo targets submitting for approval in the second half of 2026, with final results expected to be announced at a U.S. conference in November 2026. This suggests that AR1001 is likely to reach the market after 2027.
The exclusive rights for AR1001 have been secured until 2040 through additional U.S. patent registrations, indicating Arivivo's potential long-term market dominance in the dementia treatment sector.
Arivivo and Fusheng Pharmaceutical recently signed a $7 billion export contract for AR1001, marking a significant step toward global market expansion.

Progress of AR1001 Clinical Trials
The global Phase 3 clinical trials for AR1001 officially concluded on July 27, 2026. Earlier reports on July 28 stated that the main trial had ended. AR1001 has demonstrated safety and tolerability in U.S. Phase 2 clinical trials, providing a crucial foundation for moving forward with Phase 3.
Arivivo officially announced on July 21, 2026, that it plans to present the Phase 3 results at a U.S. conference in November, signaling preparations for final approval steps after data analysis is complete.
On March 24, 2026, Arivivo officially announced its target of seeking regulatory approval by the second half of 2026 following the presentation of research results. Earlier reports from October 2025 indicated that the company was focusing on commercializing 'oral dementia medicine.'
Patents and Global Market Outlook
AR1001 has secured exclusive rights until 2040 through additional U.S. patent registrations, ensuring Arivivo's long-term competitive advantage in the dementia treatment field.
The $7 billion export contract between Arivivo and Fusheng Pharmaceutical represents a strategic move for global market entry. This shows that Arivivo is not only targeting domestic markets but also building competitiveness in international markets.
AR1001 is gaining attention as a multi-target treatment candidate, suggesting potential effectiveness through simultaneous targeting of multiple mechanisms involved in Alzheimer's disease treatment.
Purchase Information for AR1001
Currently, AR1001 is still in the clinical trial phase and has not been released to the market. Therefore, purchasing is impossible, and specific pricing details have not yet been disclosed. Price information will likely be provided after approval submission and results are announced.
Arivivo's AR1001 is scheduled to present final results at a U.S. conference in November 2026, which will serve as an important step toward regulatory approval. After this, the market release timeline will become clearer.
Verified Information on AR1001
Arivivo's AR1001 is an Alzheimer's treatment drug that has completed global Phase 3 clinical trials and is currently undergoing data analysis. The company targets approval application in the second half of 2026, with final results to be announced at a U.S. conference in November 2026.
AR1001 is recognized as the world's first oral dementia treatment drug, securing exclusive rights until 2040 through additional U.S. patent registrations. Arivivo and Fusheng Pharmaceutical have signed a $7 billion export contract to support global market entry strategy.
Frequently Asked Questions
When will AR1001 be released?
The final results for AR1001 are scheduled to be announced at a U.S. conference in November 2026, leading to an expected market release after 2027.
What is the price of AR1001?
As AR1001 is currently in clinical trials, specific pricing information has not been disclosed. Price details will likely be provided after approval and results are announced.
Can I buy AR1001 before it's officially released?
No, AR1001 cannot be purchased as it has not yet been released to the market. Specific purchase methods and pricing information will only be available after 2026 following approval submission and results announcement.
Frequently Asked Questions
Arivivo's AR1001 is an Alzheimer's treatment drug that has completed global Phase 3 clinical trials and is currently undergoing data analysis. The company targets approval application in the second half of 2026, with final results to be announced at a U.S. conference in November 2026. AR1001 is recognized as the world's first oral dementia treatment drug, securing exclusive rights until 2040 through additional U.S. patent registrations.
The $7 billion export contract between Arivivo and Fusheng Pharmaceutical represents a strategic move for global market expansion. This shows that Arivivo is not only targeting domestic markets but also building competitiveness in international markets.
Currently, AR1001 cannot be purchased, and specific price information has not been disclosed. Details will likely be provided after approval submission and results are announced. Therefore, the question of 'AR1001 purchase methods and price comparison' is currently impossible to address, and readers must wait for information after 2026.
Arivivo's development of AR1001 could mark a significant milestone in dementia treatment, making it important to follow future progress closely.
You can view similar articles on this topic all at once.
View Related ArticlesFAQ
When will AR1001 be released?
The final results for AR1001 are scheduled to be announced at a U.S. conference in November 2026, leading to an expected market release after 2027.
What is the price of AR1001?
As AR1001 is currently in clinical trials, specific pricing information has not been disclosed. Price details will likely be provided after approval and results are announced.
Can I buy AR1001 before it's officially released?
No, AR1001 cannot be purchased as it has not yet been released to the market. Specific purchase methods and pricing information will only be available after 2026 following approval submission and results announcement.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 아리바이오 AR1001 구매 방법 및 가격 비교